Syndax Pharmaceuticals Inc. ( (SNDX) ) has released its Q3 earnings. Here is a breakdown of the information Syndax Pharmaceuticals Inc. presented to its investors.
Syndax Pharmaceuticals Inc. is a commercial-stage biopharmaceutical company focused on developing innovative cancer therapies, with a standout pipeline featuring the selective menin inhibitor revumenib and the FDA-approved monoclonal antibody Niktimvo™.
In its latest earnings report, Syndax announced significant progress in its pipeline, including the U.S. FDA approval of Niktimvo for chronic GVHD and the anticipated approval of revumenib for acute leukemia. The company also secured a $350 million royalty funding deal to support its journey to profitability.
Key highlights include the Priority Review status of revumenib’s NDA, with a PDUFA action date set for December 26, 2024, and the publication of pivotal trial data in the Journal of Clinical Oncology. Financially, the company reported a net loss of $84.1 million for the third quarter of 2024, driven by increased R&D and commercial readiness expenses.
Syndax’s forward-looking strategy involves expanding the use of revumenib across different leukemia types and leveraging Niktimvo’s approval to enhance its market presence. The company remains focused on reaching profitability, supported by its robust pipeline and strategic financial agreements.
